Back HIV/AIDS HIV/AIDS Topics HIV Treatment

IAS 2015: Altered Cholesterol Metabolism May Protect Immune Cells of Non-Progressors

Enhanced cholesterol metabolism in certain immune cells may help explain why some people with HIV can naturally control the virus with little or no disease progression, according to research presented at the 8th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention and at the preceding IAS Towards an HIV Cure Symposium last month in Vancouver. The findings suggest that regulating cellular cholesterol metabolism may offer a new approach to controlling HIV and potentially achieving a functional cure, or long-term remission.

alt

Read more:

IAS 2015: START Supports ART For All [VIDEO]

Full results from the Strategic Timing of Antiretroviral Treatment (START) trial provide definitive evidence that starting antiretroviral therapy (ART) soon after HIV diagnosis, rather than waiting until the CD4 T-cell count falls below 500 cells/mm3, significantly reduces the risk of AIDS-related and non-AIDS illness and death, researchers reported at the 8th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention last month in Vancouver.

alt

Read more:

IAS 2015: Targets Proliferate in HIV Cure Research

The Towards an HIV Cure two-day symposium has become a fixture in advance of the International AIDS Society conferences and the meeting last week in Vancouver featured a more varied range of experimental approaches than ever in the search for ways of eliminating HIV infection from the body.

alt

Read more:

IAS 2015: WAVES Shows Elvitegravir Regimen Beats Boosted Atazanavir for Women with HIV

A study of antiretroviral treatment specifically for women with HIV showed that a single-tablet regimen containing the integrase inhibitor elvitegravir suppressed the virus better than a regimen containing ritonavir-boosted atazanavir, according to a poster presented at the 8th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention last month in Vancouver. This study is important in part because it demonstrates that including more women in clinical trials is feasible.

alt

Read more:

White House Releases Updated National HIV/AIDS Strategy

On July 30 the White House released an updated version of its National HIV/AIDS Strategy, outlining the administration's plans through the year 2020. In keeping with recent research, the revised strategy includes an increased emphasis on early antiretroviral treatment and pre-exposure prophylaxis (PrEP), as well as focusing on underserved and heavily affected population groups including young gay men, transgender women, and African-Americans.

alt

Read more:

IAS 2015: Zinc Finger Nuclease Genome Editing [VIDEO]

Researchers used a zinc finger nuclease protein to delete a gene for the CCR5 receptor from stem cells in monkeys, an advance that could play a role in efforts to achieve a functional cure for HIV, according to a report at the 8th International AIDS Society Conference on HIV Pathogenesis, Treatment, and Prevention last month in Vancouver.

alt

Read more:

IAS 2015: Long-term HIV Remission [VIDEO]

A French teenager with HIV who has maintained an undetectable viral load for 12 years while off antiretroviral treatment was among the most widely discussed topics at the 8th International AIDS Society Conference last week in Vancouver. While no one is calling this case a cure, it does raise interesting questions about "post-treatment control" and may provide clues about how to achieve a functional cure or long-term HIV remission.

alt

Read more: